18th February 2021, 12.30-17.00 GMT
This symposium brings together pharmaceutical industrialists, regulators, policy makers and academics to look at how the community can grow medicines manufacturing in the UK and accelerate the adoption of advanced manufacturing and digital technologies. To achieve this we need an integrated approach, harnessing the combined efforts of the stakeholders to lead the transformation that will enhance quality, cost and sustainability of medicines manufacture, ultimately for the benefit of patients.
Programme can be downloaded here
Regulatory: Protect and improve public health by enabling the earliest access and high-quality supply of safe, effective, and innovative products through proportionate, data-driven decisions on risk and benefits
Industry: Leveraging the combined UK Innovation Ecosystem to deliver a more agile, adaptable and scalable medicine manufacturing supply chain
Academia: Highlight strategic commitment to world class research and innovation for advanced manufacturing technologies, sustainability and to build the talent pipeline, developing existing assets
This meeting is hosted by the joint MIT CMAC ISCMP Steering Team. Registration and attendance at no charge to participants.
Continuous flow chemical reactor manufacturer Laminar Co Ltd (Jungwon-gu, Republic of Korea), represented in the UK and Ireland by Analytik Ltd (Cambridge, UK), have joined the CMAC Future Manufacturing Research Hub as tier 2 members from October 2020.
Laminar manufactures the world’s first commercially available chemical reactors which utilise Taylor Fluid Flow to synthesize high-purity, uniform substances. The patented design chemical reactors use a jacketed cylindrical vessel with a central, rotating agitation bar to produce Taylor Flow mixing along the length of the vessel resulting in 3-times faster mass flow transfer compared to tank type reactors.
The partnership will see the first Taylor Flow Reactor installed in the UK at CMAC’s Technology Innovation Centre (TIC) site in Glasgow, which will initially be studied to greater understand the mechanisms and potential of the technology, explore new syntheses and be benchmarked against existing processes. The CMAC Future Manufacturing Research Hub brings together a research team at Strathclyde, as well as other leading academic groups and an array of industry partners to address the urgent need to translate new molecules into high-value products through rapid predictive development pathways and integrated continuous manufacturing systems.
Analytik announced a partnership with Laminar to distribute their Taylor Flow Reactors in the UK and Ireland in 2019. Specialists in providing and supporting pioneering technology, it will oversee the installation of a Tera3100-HC Laminar Continuous Taylor Reactor (LCTR®) at CMAC in early 2021, as well as provide ongoing technical and service support over 3 years.
Speaking about the membership, Ian Laidlaw, Managing Director at Analytik said “We are delighted to be joining the CMAC Future Manufacturing Research Hub and excited to be facilitating the first LCTR® chemical reactor installation in the UK. This fantastic technology sets a new standard for high yield synthesis of high-purity, uniform substances and offers faster, more efficient continuous processing”.
Professor Alastair Florence, Director of CMAC added “It is a pleasure to welcome Laminar and Analytik to CMAC’s community. This partnership brings exciting new opportunities for our research team to work with this unique Taylor Flow Reactor platform to explore the potential for this advanced technology across reaction, work-up, purification and particle engineering for pharmaceutical systems. This technology will extend our Digital Twin and MicroFactory platforms for continuous manufacturing and create real benefits and impacts to our stakeholders though enabling faster process and product development and reducing the cost and environmental impact of medicines manufacture.”
You can find out more about Laminar Continuous Taylor Reactors (LCTR) by visiting the Analytik website: https://analytik.co.uk/product/continuous-flow-reactor/.
The LCTR®-Tera 3100 & 3300.
The CMAC Future Manufacturing Research Hub will address the urgent need to translate new molecules into high-value products through rapid predictive development pathways and integrated continuous manufacturing systems, enabling more personalised, responsive and flexible product provision through digitalised supply chains. Building on the significant success of the EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, and informed by extensive engagement with national and global industry, end-users, technology providers, international academic programmes and regulatory agencies, the industry-academic team has co-created an ambitious CMAC Future Manufacturing Research Hub Vision. www.cmac.ac.uk
For over 15 years Analytik has been a trusted supplier of cutting-edge scientific instrumentation to leading organisations throughout the UK and Ireland. Specialists in providing and supporting pioneering technology, it delivers added value through specialised consultative expertise and comprehensive pre- and post-sales support to ensure that customers get the most out of their investment. For further information please visit http://analytik.co.uk/.
Founded in 2010, South Korean-based Laminar has patented the world’s first commercially available Taylor Flow Reactor (LCTR®) and continues to develop manufacturing processes and expand its product range, which can be applied to various fields, such as secondary batteries, pharmaceuticals, graphene oxide, food additives and nanomaterials.
Karina Davies, Analytik – firstname.lastname@example.org
Stewart Mitchell, CMAC – email@example.com
CMAC and PwC are delighted to share ‘The Business Case Insights for Continuous Manufacturing’. This joint document, with input from industrial partners, seeks to review key considerations for building a successful business case for the industrial adoption of innovative Continuous Manufacturing (CM) technologies.
The report is written from the perspective of the CMAC manufacturing research programme stakeholders. Hence, it targets factors directly relevant to continuous small molecule pharmaceutical manufacture and although addresses the many drivers and impacts across the entire value chain, brings a strong emphasis on factors relevant to continuous drug substance manufacture.
With the associated growth in new technologies and services comes the opportunity for different business models that exploit CM to deliver additional value and tackle major challenges facing the sector: how are we to manage spiralling prescription medicine costs in the NHS and other global healthcare systems; can the pharmaceutical supply chain deliver greater personalisation of medicines quickly and cost effectively; can the security of global medicines supply be assured to maintain access to essential medicines or respond to medical emergencies; how can the impact of medicines manufacture on the environment be minimised and made more sustainable? Those that can best harness the potential of innovative technologies such as CM will be best placed to meet these challenges.
Nine critical considerations have been highlighted for business case development. Through each of these lenses, a holistic case for continuous manufacturing can be progressed to help drive the uptake of this currently novel technology.
Please view full document here
This document was undertaken with engagement from CMAC Tier 1 partners AstraZeneca, Eli Lilly, Pfizer and Takeda as well as leveraging CMAC’s own extensive academic portfolio on end-to-end (E2E) processing. CMAC would like to thank all those who have contributed information and viewpoints on key technical aspects in combination with PwC’s wider business case perspective, to help inform and engage senior stakeholders and drive continuous manufacturing forward.
CPI, an independent technology innovation centre and founding member of the UK Government’s High Value Manufacturing Catapult, has today announced the launch of SCOUT, a project to target a breadth of Scottish SMEs working in the high value chemical and biochemical supply chains. The project will leverage technology within CPI and its partner organisations to accelerate and de-risk the growth of Scottish SMEs – including those underserved and remote – by enabling new partnerships and increased technology adoption.
The SCOUT project, which will run over the next three years, will be led by CPI’s Medicines Manufacturing Innovation Centre and is being launched in collaboration with CMAC Future Manufacturing Research Hub and the Industrial Biotechnology Innovation Centre (IBioIC). It aims to serve Scottish SMEs through a three-pronged approach of innovation clinics (currently planned to start in late 2020), Innovation Integrator assessments and deep technical consultancy. The £882k Scottish Outreach (SCOUT) project is jointly funded by the European Regional Development Fund (managed by Scottish Enterprise) CPI, CMAC and IBioIC.
Fifty SMEs from across Scotland will be selected to attend the planned innovation clinics, supported by all of the partner organisations. Companies will be connected to new networks and supply chains in order to encourage partnerships and attend workshops with a focus on common technology and business challenges, including equality, sustainability and diversity. As location can often act as a barrier to event attendance, two innovation clinics will be located in central Scotland, while the other two will be located in the Highlands & Islands region.
CPI will also provide promising SMEs with Innovation Integrator assessments, a proprietary diagnostic tool used to identify innovation gaps, prioritise resources, and both assess and improve the market readiness of a product or process. Finally, deep technical consultancy – supported by all project partners – will provide selected SMEs with the opportunity to receive knowledge and expertise on specific topics, as well as providing the next steps for implementing specific recommendations.
The SCOUT project aims to drive future economic growth in Scotland, providing services for underserved Scottish SMEs and ensuring previous barriers – as a result of geographical or technical limitations – are removed. This connection and support will ultimately generate new ideas and revenue, helping to accelerate the delivery of disruptive technology to the market.
Professor Alastair Florence, Director, CMAC Future Manufacturing Research Hub, said: “This is an exciting opportunity for the Scottish research, innovation and SME community to stand out. Access to innovation clinics and consultancy, supporting all of Scotland, will allow new and unique services and products to enter the market and support economic growth at a time when this is more important than ever. This inventive, collaborative approach would not have been possible without the SCOUT project. The CMAC Future Manufacturing Research Hub works in partnership with industry and the supply chain to transform medicines development and manufacture.”
Dr Mark Bustard, CEO, IBioIC, said: “IBioIC is delighted to work with CPI on the SCOUT project. Alongside CMAC, IBioIC will support our industry members and Scotland’s wider Industrial Biotechnology community to ensure that the SMEs can take advantage of the tools created through the SCOUT project to accelerate the exploitation of their innovations.”
Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre at CPI, said: “The SCOUT project is providing Scottish SMEs in the high value chemical and biochemical supply chains with a great opportunity to drive forward the Scottish economy once the COVID-19 pandemic is over”.
CPI is an independent technology innovation centre and a founding member of the UK Government’s High Value Manufacturing Catapult. Founded in 2004, CPI applies its years of experience across a broad range of industries to ensure that every great invention gets the best opportunity to become a successfully marketed product.
CPI’s integrated approach provides its partners with a unique combination of assets, expertise and skills to drive successful innovation. With a deep understanding of innovation processes and funding, outstanding technical expertise and industry-relevant assets, CPI enables products and processes to be quickly and cost-effectively brought to market. By employing bright minds from both academia and industry, CPI helps create a bespoke team that will provide the right support, helping you to navigate the route to commercialisation while reducing risk along the way.
We form connections throughout the supply chain, bringing together investors, government organisations and academic institutions to facilitate the necessary partnerships for effective innovation. This increases productivity across industries and supports the development of next-generation manufacturing, highly-skilled jobs and economic growth for the UK.
EPSRC CMAC Future Manufacturing Hub is an international hub of excellence for medicines manufacturing research, led from the University of Strathclyde, comprises academic investigators and research staff across 7 leading universities. Our vision is to lead the world in advanced pharmaceutical manufacturing underpinned by our MicroFactory and digitalisation strategy. Established in 2011, CMAC’s vision has been developed through close collaboration with industry and the support of its Tier 1 partners: AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Roche and Takeda. Working in partnership with industry, its purpose is to transform current manufacturing processes into the medicine supply chain of the future.
For more information visit www.cmac.ac.uk
The Industrial Biotechnology Innovation Centre (IBioIC) is a networking and support organisation that connects industry, academia and government to bring biotechnology processes and products to the global market. It does this by offering scale-up facilities, talent development, funding provision, and promotion of Scotland’s unique assets.
IBioIC was established in 2014 to fulfil the aims of the National Plan for Industrial Biotechnology to grow a £900m biotechnology industry in Scotland by 2025. Biotechnology uses plant-based and waste resources to produce or process materials, chemicals and energy, offering green and sustainable alternatives to fossil fuels in everything from energy to medicines to food packaging.
IBioIC supports over 130 companies, 50 research projects, and works with 18 Scottish universities and research institutes. IBioIC is hosted by the University of Strathclyde in Glasgow’s Innovation District.
The Advancing Manufacturing Challenge Fund is a partnership between the Scottish Government, Scottish Enterprise, and Highlands and Islands Enterprise. A full list of successful projects is available on the AMCF website. Total investment is £15.8 million, with £8.3 million from the European Regional Development Fund, £590,000 from the Scottish Government, and the remainder in match-funding from the chosen projects.
The Scottish Government is the Managing Authority for the European Structural Funds 2014-20 Programme. For further information visit our webpages or follow @scotgovESIF.
In response to the Covid-19 outbreak and following advice from the WHO, the UK and Scottish Governments, the University of Strathclyde has taken the decision to restrict highly populated areas in the interest of student and staff safety. Therefore CMAC has closed all laboratory and office areas.
As we anticipated this would be a possible course of action, we have been able to minimize the disruption and impact to active projects. Our staff will be working remotely, and you will be contacted by the project lead, project manager or business development manager to advise you on your specific project and the impact to project timelines.
In planning for the potential impact of the evolving coronavirus situation, the safety, health and wellbeing of the staff and students is our priority. Thank you for your understanding.
MIT-CMAC International Symposium on Continuous Manufacturing of Pharmaceuticals
An Integrated Ecosystem for Transforming Medicines Manufacturing
18th February 2021, 12.30-17.00 GMT
This symposium brings together pharmaceutical industrialists, regulators, policy makers and academics to look at how the community can grow medicines manufacturing in the UK and accelerate the adoption of advanced manufacturing and digital technologies. To achieve this we need an integrated approach, harnessing the combined efforts of the stakeholders to lead the transformation that will enhance quality, cost and sustainability of medicines manufacture, ultimately for the benefit of patients. .... more
Laminar and UK/IRE Distributor Analytik Join CMAC Future Manufacturing Research Hub
Continuous flow chemical reactor manufacturer Laminar Co Ltd (Jungwon-gu, Republic of Korea), represented in the UK and Ireland by Analytik Ltd (Cambridge, UK), have joined the CMAC Future Manufacturing Research Hub as tier 2 members from October 2020..... more